United States

Navidea Biopharmaceuticals Inc (NAVB.A)

NAVB.A on American Stock Exchange

18 Aug 2017
Change (% chg)

$-0.00 (-0.20%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Select another date:

Tue, Aug 8 2017

BRIEF-Navidea Biopharmaceuticals reports Q2 loss per share $0.03

* Navidea Biopharmaceuticals reports second quarter 2017 financial results

BRIEF-Navidea says on June 26, co and FTI Consulting entered into settlement agreement

* Navidea biopharmaceuticals inc - on june 26, co and fti consulting entered into a settlement agreement - sec filing

BRIEF-Navidea enters exclusive license, distribution agreement for India with Sayre Therapeutics

* Navidea enters exclusive license and distribution agreement for India with Sayre Therapeutics

BRIEF-Navidea says commercial partner Norgine launches lymphoseek in Europe

* Navidea’s commercial partner, Norgine B.V., launches lymphoseek in Europe

BRIEF-Navidea Biopharmaceuticals reports Q1 earnings $0.53/shr

* Navidea Biopharmaceuticals reports first quarter 2017 financial results

BRIEF-Navidea Q4 loss per share $0.02

* Navidea provides corporate update and reports full year 2016 results

BRIEF-Navidea Biopharmaceuticals files for non timely 10-K

* Navidea biopharmaceuticals files for non timely 10-k - sec filing

BRIEF-Cardinal Health reports 5.8 pct passive stake in Navidea Biopharma

* Cardinal Health, Inc reports 5.8 percent passive stake in navidea biopharmaceuticals inc as of March 3, 2017 - sec filing Source text for Eikon: Further company coverage:

Select another date: